Ro 23-9424 is a dual-action cephalosporin with an aminothiazolylmethoxyimino-type side chain at the 7 position and fleroxacin esterified at the 3' position. The new compound has broad and potent antibacterial activity in vitro and in vivo, reflecting contributions from both the , (-lactam Ro 23-9424 is a cephalosporin with an aminothiazolylmethoxyimino-type side chain at the 7 position and fleroxacin esterified at the 3' position (1). Ro 23-9424 has broad and potent antibacterial activity in vitro (2, 9, 12) and in vivo (3). The antibacterial spectrum reflects contributions of both the cephalosporin moiety (notably, streptococci) and the quinolone moiety (notably, ,-lactamase-overproducing strains). Ro 23-9424 binds to penicillin-binding proteins and inhibits replicative DNA biosynthesis (8). These observations have led to the use of the term "dual-action cephalosporins" for Ro 23-9424 and analogous compounds (1, 8) .
Ro 23-9424 is a cephalosporin with an aminothiazolylmethoxyimino-type side chain at the 7 position and fleroxacin esterified at the 3' position (1) . Ro 23-9424 has broad and potent antibacterial activity in vitro (2, 9, 12) and in vivo (3) . The antibacterial spectrum reflects contributions of both the cephalosporin moiety (notably, streptococci) and the quinolone moiety (notably, ,-lactamase-overproducing strains). Ro 23-9424 binds to penicillin-binding proteins and inhibits replicative DNA biosynthesis (8) . These observations have led to the use of the term "dual-action cephalosporins" for Ro 23-9424 and analogous compounds (1, 8) .
It was originally proposed by O'Callaghan et al. (15) that the second "warhead" of such a cephalosporin, in this case, the fleroxacin moiety of Ro 23-9424, is released when the ,-lactam ring is opened by a bacterial enzyme, such as a P-lactamase. In the case of Ro 23-9424, active quinolone may also be released by enzymatic or nonenzymatic hydrolysis of the ester linkage. It is well known that 3'-acetoxy cephalosporins, such as cephalothin, cephapirin, and cefotaxime, are deesterified in vivo to form 3-hydroxymethylcephalosporins (4, 5, 19) . These metabolites have antibacterial activity, but they are less potent than the acetylated cephalosporins. Hydrolysis of the ester bond of Ro 23-9424 presumably results in the formation of fleroxacin and the 3-hydroxymethylcephalosporin desacetylcefotaxime, both of which have antibacterial activity. The extent to which Ro 23-9424 exerts the proposed mechanism of action in vivo (wherein the quinolone is released by a bacterial process), or acts as a combination of active metabolites, is therefore determined by its pharmacokinetic properties. This study * were as follows: mouse, 66%; rat, 76%; dog, 52%; monkey, 72%; and human, 66%. Single-dose pharmacokinetics in animals. Pharmacokinetic profiles of Ro 23-9424 were determined in mice (Fig. 2) , rats ( Fig. 3) , dogs (Fig. 4) , and baboons ( Table 1 . Comparative data for cefotaxime are also shown.
Concentrations of fleroxacin in plasma were low (about 1 jig/ml) but persistent. In mice, fleroxacin concentrations fell below the detection limit at 1 h, but trace concentrations were found at 4 and 8 h (data not shown). Fleroxacin was detectable up to 8 h in the rat and 24 h in the dog and the baboon (24 h time point not shown). The relatively rapid disappearance of Ro 23-9424 from the plasma without a corresponding increase in fleroxacin concentration suggested a model in which Ro 23-9424 is primarily eliminated by excretion of the intact molecule into the urine or the bile (as is typical of cephalosporins), rather than by hydrolysis to desacetylcefotaxime and fleroxacin.
Such a model would predict that the intact molecule should be found in the urine, feces, or both. Under the conditions of these experiments, a quantitative analysis of urinary and fecal recovery of drug was not attempted. However, baboon urine was collected during the first 8 h and 8 to 24 h after dosing. Concentrations of Ro 23-9424 in the range of 96 to 375 ,ug/ml were found in the samples obtained from 0 to 8 h and concentrations of 29 to 63 ,ug/ml were found in the samples obtained from 8 to 24 h. In another experiment, Ro 23-9424 was administered to mice (20 mg/kg, intravenously) under light methoxyflurane anesthesia. Under these conditions, the animals do not urinate and urine was aspirated from the bladders at various times. As shown in Table 2 , concentrations of intact Ro 23-9424 in urine were high and generally exceeded those of fleroxacin.
Multiple-dose pharmacokinetics in baboons. Ro 23-9424 (20 mg/kg, intravenously) was administered once daily for 14 days. On days 2 (the animals were not properly dosed on day 1), 7, and 14, samples for a complete plasma profile were obtained. On other days, only trough and peak samples were taken. The results for days 2 through 14 are summarized in Fig. 6 . On day 4, concentrations of both Ro 23-9424 and fleroxacin in plasma were lower than expected, but with this exception, the peak and trough levels of both drugs were quite reproducible from days 3 to 14. Trough levels of Ro 23-9424 were undetectable, while peak levels averaged 142 jig/ml on days 5 through 14. Trough levels of fleroxacin averaged 0.4 jig/ml and peak levels averaged 2.9 jig/ml. The highest peak concentration of fleroxacin in any individual sample was 4.9 ,ug/ml. DISCUSSION Results of this study suggest a model in which Ro 23-9424 is primarily eliminated by excretion of the intact molecule (as is typical of cephalosporins), rather than by hydrolysis to desacetylcefotaxime and fleroxacin. The validity of this model could be tested by analyzing the recovery of the intact molecule and its metabolites in the urine and feces. Given the difficulty of collecting animal excreta under the experimental conditions and the suspected instability of the drug under those conditions, no attempt was made to quantitate the total recovery of Ro 23-9424 in the excreta. The concentrations found in baboon and mouse urine, however, were sufficient to indicate that urinary excretion of the intact molecule is a major route of elimination of Ro 23-9424, as it 10  306  47  20  328  32  30  630  80  40  498  75  60  438  90  120  414  132 is for cefotaxime. Ro 23-9424 has been chosen for clinical trials, and this hypothesis will soon be tested in humans in whom urine collection is logistically simpler than it is in animals.
Cefotaxime is the logical compound for pharmacokinetic comparison with Ro 23-9424, since it has the same 7-acylamino substituent and is also esterified at the 3' oxygen. Cefotaxime is known to be deesterified in vivo to form desacetylcefotaxime, which may be further metabolized (5) . Cefotaxime is stable in whole blood, but is degraded by hemolyzed blood and tissue homogenates, forming desacetylcefotaxime and other metabolites (5) . Nevertheless, 40 to 60% of an intravenously administered dose in humans may be recovered as the unchanged molecule in urine (7) .
The pharmacokinetic similarities of the two compounds are illustrated by the data in Table 1 , in which the pharmacokinetic parameters of Ro 23-9424 are compared with those of cefotaxime. Surprisingly, there is very little published data on the pharmacokinetics of cefotaxime in mice. The half-life of 18 min reported for cefotaxime by Murakawa et al. (14) after subcutaneous administration is, however, consistent with the 13-min half-life after intravenous administration of Ro 23-9424 in the present study.
In rats, the pharmacokinetic parameters of Ro 23-9424 are quite similar to those reported for cefotaxime by Omosu et al. (16) , except that the systemic clearance rate for cefotaxime is somewhat greater than that for Ro 23-9424 (Table 1) .
Two studies of cefotaxime pharmacokinetics in dogs have appeared (10, 17 [11, 18] ). Third, desacetylcefotaxime generally has much lower antibacterial activity than fleroxacin (except against a few species, notably, streptococci). In short, (i) desacetylcefotaxime is the less important metabolite, and (ii) an upper limit can be placed on its concentration without assaying it directly. Therefore, desacetylcefotaxime concentrations were clearly of secondary interest.
We did assay for desacetylcefotaxime using a modified assay method in one set of rat samples (data not shown). Except for the first sample (taken as soon as possible after drug administration), which contained 1.3 ,ug of desacetylcefotaxime per ml, only traces of desacetylcefotaxime were found, and these disappeared completely after 12 min. Although this assay method was not fully validated, the results do support the rationale given above.
Some fieroxacin is apparently formed from Ro 23-9424 in vivo. Since the half-lives of Ro 23-9424 and fleroxacin are substantially different-17 min versus 2.65 h (13) in the rat, for example-it appeared possible that levels of fleroxacin in plasma might accumulate to unacceptable levels on repeated dosing with Ro 23-9424. The multiple-dose study in baboons showed only a slight accumulation of fleroxacin, however. Peak fleroxacin concentrations were no higher than 4.9 ,ug/ml, which is comparable to that found in humans after a normal oral dose of 400 mg of fleroxacin (18, 20) . The dose regimen in this multiple-dose study was only once daily to avoid undue stress to the animals. Somewhat greater accumulation of free fleroxacin may be expected at the anticipated human dosing frequency of two or three times daily.
Although some fleroxacin is produced in vivo, Ro 23-9424 must be considered as a therapeutic agent in its owr right, not simply as a prodrug, just as cefotaxime is considered to be a therapeutic agent. Unlike cefotaxime, however, one of the metabolic products of Ro 23-9424, fleroxacin, is at least as active as the parent molecule against many strains of bacteria.
The low but persistent concentrations of fleroxacin produced metabolically may have significant therapeutic effects and must also be considered in analyzing the in vivo activity of Ro 23-9424. The persistence of fleroxacin after elimination of Ro 23-9424 is a phenomenon that requires further investigation. A reasonable working hypothesis is that there is some biliary excretion of Ro 23-9424. Drug excreted in the bile would be hydrolyzed in the gut to fleroxacin and desacetylcefotaxime or other by-products. The fleroxacin so formed could then be reabsorbed from the gut.
